Relmada Therapeutics, Inc.

NASDAQ:RLMD

Biotechnology

Healthcare
$2.86 -0.97%

-$0.06 today

Market cap
$304.61M
Beta
0.39
P/E (TTM)
-9.6
EPS (TTM)
-$0.68
52W Low $0.52High $8.00

Volume 1.86M

Average 1.24M

RLMD Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

No reported Gross Margin figures are available to summarize.

Gross Margin history

Percent of revenue · from the income statement

No Gross Margin data reported for this period type.

Gross Margin vs competitors

How RLMD compares with its peers on the latest reported figures

RLMD Competitors Peer median
Gross Margin for RLMD and competitors
Company Period LTM level YoY 3-year change
VXRTVaxart, Inc.LTM Mar 2026100.0% +0.0 pp+0.0 pp
TCRXTScan Therapeutics, Inc.LTM Mar 202692.4% -7.6 pp-27.8 pp
CBUSCibus, Inc.LTM Mar 202672.1% +8.5 pp+814.3 pp
FBIOFortress Biotech, Inc.LTM Mar 202664.5% +3.3 pp+7.6 pp
RLMDRelmada Therapeutics, Inc.FY2025— ——
IMUXImmunic, Inc.FY2025— ——
PMVPPMV Pharmaceuticals, Inc.FY2025— ——
ACRVAcrivon Therapeutics, Inc. Common StockFY2025— ——
ACETAdicet Bio, Inc.FY2025— ——
Peer median (excluding RLMD) 82.2%+1.7 pp+3.8 pp

Competitors are the stored peer set for RLMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development90.62M113.32M54.81M46.18M744.56K
Selling, General & Admin35.08M47.93M48.9M37.72M311.9K
Operating Expenses125.7M161.25M103.7M83.89M59.1M
Depreciation & Amortization1.26K2K103.7M00
EBITDA(125.75M)(157.04M)4.91M(79.98M)(57.39M)
EBITDA Margin—————
Operating Income(125.7M)(161.25M)(103.7M)(83.89M)(59.1M)
Operating Margin—————
Interest Income1.2M2.66M5.15M3.53M1.4M
Interest Expense00000
Other Income / Expenses(48.32K)4.21M4.91M3.91M1.72M
Income Before Tax(125.75M)(157.04M)(98.79M)(79.98M)(57.39M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(125.75M)(157.04M)(98.79M)(79.98M)(57.39M)
Net Margin—————
EPS (Basic)(7.16)(5.30)(3.28)(2.65)(1.45)
EPS (Diluted)(7.16)(5.30)(3.28)(2.65)(1.45)
Weighted Avg Shares17.55M29.63M30.1M30.16M39.48M
Weighted Avg Shares (Diluted)17.55M29.63M30.1M30.16M39.48M

Relmada Therapeutics, Inc.

NASDAQ:RLMD

Intrinsic Alpha fair value

Locked

Current Price

$2.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.